Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb 26:14:1327055.
doi: 10.3389/fonc.2024.1327055. eCollection 2024.

Current therapies and progress in the treatment of advanced gastric cancer

Hongyu Li  1 , Ming Shen  1 , Shihao Wang  1
Affiliations
Review

Current therapies and progress in the treatment of advanced gastric cancer

Hongyu Li et al. Front Oncol. .

Abstract

Gastric cancer (GC) remains one of the most life-threatening disease worldwide with poor prognosis because of the absence of effective treatment and the delay in diagnosis. Due to the delay of diagnosis, a large proportion of GC patients are diagnosed as advanced GC, with extreme short lifespan. In the past few years, some pivotal progress and novel therapies was proposed, and conducted into clinical researches and practice. In this study, we summarized the development of several novel immunotherapy or targeted treatment modalities for advanced GC, including immune checkpoint inhibitors, anti-angiogenic therapy and cancer vaccines. Additionally, the advantage and potential weakness in each of these therapeutic methods are also listed. Finally, we discussed the promising research direction of advanced GC treatment, and the limitation in basic and clinical research of advanced GC, including the combination of immunotherapy and targeted therapy.

Keywords: advanced gastric cancer; anti-angiogenic therapy; immune checkpoint inhibitors; immunotherapy; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Molecular Classification of Gastric Cancer.
Figure 2
Figure 2
Components of effective immunotherapy in gastric cancer.
See this image and copyright information in PMC

References

    1. Yoon J, Kim TY, Oh DY. Recent progress in immunotherapy for gastric cancer. J Gastric Cancer (2023) 23:207–23. doi: 10.5230/jgc.2023.23.e10 - DOI - PMC - PubMed
    1. Sexton RE, Al Hallak MN, Diab M, Azmi AS. Gastric cancer: a comprehensive review of current and future treatment strategies. Cancer Metastasis Rev (2020) 39:1179–203. doi: 10.1007/s10555-020-09925-3 - DOI - PMC - PubMed
    1. Jin X, Liu Z, Yang D, Yin K, Chang X. Recent progress and future perspectives of immunotherapy in advanced gastric cancer. Front Immunol (2022) 13:948647. doi: 10.3389/fimmu.2022.948647 - DOI - PMC - PubMed
    1. Khan S, Cho WC, Hussain A, Azimi S, Babadaei MMN, Bloukh SH, et al. The interaction mechanism of plasma iron transport protein transferrin with nanoparticles. Int J Biol Macromol (2023) 240:124441. doi: 10.1016/j.ijbiomac.2023.124441 - DOI - PubMed
    1. Khan S, Vahdani Y, Hussain A, Haghighat S, Heidari F, Nouri M, et al. Polymeric micelles functionalized with cell penetrating peptides as potential pH-sensitive platforms in drug delivery for cancer therapy: A review. Arab J Chem (2021) 14:103264. doi: 10.1016/j.arabjc.2021.103264 - DOI